Targeting cellular senescence in adipose tissue: a potential treatment for type 2 diabetes
H. B. Jung, E. C. Kim, H. K. Sung, J. R. Kim, S. Y. Park
Full text PDF 
( Download count: 197)
AbstractCellular senescence refers to the cessation of cell proliferation that can be triggered by endogenous and exogenous stimuli, such as telomere dysfunction, DNA damage, and oncogenic gene expression (Di Micco et al, 2021). Senescent cells release senescent-associated secretory phenotype (SASP), which turns neighboring normal cells into senescent cells. As the accumulation of senescent cells compromises tissue repair and function, cellular senescence eventually leads to tissue aging and aging-related chronic diseases, including type 2 diabetes. Therefore, killing the senescent cells (senolytics) or reversing the senescent cells to young cells (senomorphics) can prevent or alleviate aging and aging-associated diseases (Niedernhofer and Robbins 2018). Recently, previous studies showed the reduction in senescent cells in adipose tissue attenuates insulin resistance in high-fat diet (HFD)-fed obese mice, suggesting that targeting cellular senescence in adipose tissue could be the potential treatment for type 2 diabetes (Smith et al 2021). Currently, however, there is no clinically available effective senotherapy. In our study, we aimed to find a novel senotherapy for adipose tissue aging and insulin resistance.Keywords: cellular senescence, adipose tissue, insulin resistance, senotherapy, obesity
H. B. Jung, E. C. Kim, H. K. Sung, J. R. Kim, S. Y. Park (2022). Targeting cellular senescence in adipose tissue: a potential treatment for type 2 diabetes. Gerontechnology, 21(s),2-2
https://doi.org/10.4017/gt.2022.21.s.808.2.sp3